Larotrectinib Approved in Europe for NTRK+ Tumors

Sep 23, 2019 – The European Commission has approved larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. The approval is based on data from patients enrolled across a phase I trial (LOXO- … (leggi tutto)